Firms

Droia Ventures

Droia Ventures

Zaventem, Belgium · Luxembourg, Luxembourg · Leuven, Belgium

droiaventures.comlinkedin.com

Droia Ventures is a specialist biotechnology investment and company-building group focused on therapeutics for oncology and genetic diseases. It invests globally in young drug developers and uses in-house biology, translational research and clinical-development experience to help companies progress toward clinical proof of concept. Its public legal/contact footer distinguishes Droia SA in Luxembourg, the Belgian Droia Ventures office in Zaventem, and Metaptys NV / Droia Labs in Leuven. Droia Labs is the group’s scientific validation arm rather than a separately attributed financing buyer. Current own portfolio exposure includes ALS precision medicines at QurAlis, neurodegeneration at Muna Therapeutics, rare genetic neurodevelopmental conditions at Mahzi, neuroinflammation at Montis and neuroscience-related kinase programmes at Alesta. These are development mandates rather than proven clinical outcomes. The public directory lists33 investment, operating, laboratory and advisory people with their functions explicitly scoped. Its own final-close announcements verify EUR150M for the second oncology fund in December2018 and EUR220M for Droia Genetic Disease, the third fund, in May2021. Droia I is established by the second-fund announcement but its cash size and exact close date are undisclosed. The older Droia Oncology Ventures / droiagroup.com brand is linked by the group’s own fund history; separate managed funds retain their identities. AUM figures are not additional fundraise events. Founding-year sources differ (company socialprofile2011 versus regionalagency2014), so a single legal-founding year is not asserted.

Founded
—
Type
Venture capital

Funds3

  • Droia Genetic Disease — third fund€220M

    Own announced finalclosing EUR220M May11,2021, dedicatedearlystage geneticdisease therapeutics; parallel oncologyfunds remain distinct. USD265Mquotedconversion not secondfund.

  • Droia II — second oncology fund€150M

    Actual issuerannounced finalclose EUR150MDecember10,2018. Totalfundcommitments, not corporateAUM orindividualcheque.

  • Droia I — first oncology fund—

    Firstfund explicitly verified by issuer secondfund announcement; fullyallocated as December2018, actualfundsize/close dateunknown. No estimated60–75M inferred.

Team

Operations and support

Alexander DepauwAlexander DepauwGeneral Counsel
Dan NomuraDan NomuraInvestment Advisory Board
Diether LambrechtsDiether LambrechtsInvestment Advisory Board
Eric RowinskyEric RowinskyInvestment Advisory Board
Evelien VerdrenghEvelien VerdrenghOffice Manager & Executive Assistant
George GolumbeskiGeorge GolumbeskiPartner
Guy EelenGuy EelenVP R&D – Droia Labs
Hendrik P.N. SchollHendrik P.N. SchollInvestment Advisory Board
Janwillem NaesensJanwillem NaesensManaging Partner Oncology & Droia Group
Jens Van fraeyenhoveJens Van fraeyenhoveInvestment Analyst
Jo BuryJo BuryInvestment Advisory Board
Joris SouffreauJoris SouffreauSenior Technician – Droia Labs
Kathleen SonckKathleen SonckPrincipal Scientist – Droia Labs
Katleen BrepoelsKatleen BrepoelsSenior Technician – Droia Labs
Luc DochezLuc DochezManaging Partner Genetic Disease
Luc VerelstLuc VerelstFounder & Chairman
Ludo Van Den BoschLudo Van Den BoschInvestment Advisory Board
Mathias De DeckerMathias De DeckerSenior Associate
Mathias DeclercqMathias DeclercqPrincipal
Matthew Vander HeidenMatthew Vander HeidenInvestment Advisory Board
Matthias Van WoenselMatthias Van WoenselPartner
Nathalie De BlieckNathalie De BlieckDirector of Accounting
Nathan TopsNathan TopsBusiness Development Analyst
Nele VandervoortNele VandervoortSenior Scientist – Droia Labs
Roderick BeijersbergenRoderick BeijersbergenInvestment Advisory Board
Sara MorrenSara MorrenChief of Staff to Managing Partner
Sebastian BernalesSebastian BernalesVenture Partner
Sergio QuezadaSergio QuezadaInvestment Advisory Board
Simona TalpauSimona TalpauAccountant
Sophie BernierSophie BernierCompliance Manager
Tirtha ChakrabortyTirtha ChakrabortyVenture Partner
Willem-Jan WollantsWillem-Jan WollantsScientist – Droia Labs
Xin-An LinXin-An LinVP Finance

Co-investing

Amgen Ventures
Dementia Discovery Fund
Dolby Family Ventures
INKEF Capital
Mission BioCapital

Investments